Altamira Therapeutics Ltd.
CYTOF
$0.10
$0.0223.63%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -767.50K | -767.50K | -2.06M | -2.06M | -2.17M |
| Total Depreciation and Amortization | 38.80K | 38.80K | 33.10K | 33.10K | 30.40K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -395.00K | -395.00K | 773.40K | 773.40K | 320.90K |
| Change in Net Operating Assets | 431.60K | 431.60K | -202.50K | -202.50K | 216.70K |
| Cash from Operations | -692.10K | -692.10K | -1.45M | -1.45M | -1.60M |
| Capital Expenditure | -- | -- | -51.50K | -51.50K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | 0.00 | 0.00 | 100.00 |
| Other Investing Activities | -200.00 | -200.00 | -6.40K | -6.40K | 300.00 |
| Cash from Investing | -200.00 | -200.00 | -58.00K | -58.00K | 300.00 |
| Total Debt Issued | 219.20K | 219.20K | -- | -- | -- |
| Total Debt Repaid | -31.60K | -31.60K | -32.40K | -32.40K | -36.50K |
| Issuance of Common Stock | -- | -- | 2.36M | 2.36M | 1.32M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -3.70K | -3.70K | -336.50K | -336.50K | -28.20K |
| Cash from Financing | 184.00K | 184.00K | 2.00M | 2.00M | 1.26M |
| Foreign Exchange rate Adjustments | 3.60K | 3.60K | -15.80K | -15.80K | 10.10K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -504.70K | -504.70K | 466.60K | 466.60K | -334.10K |